http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/list Mynewsdesk nyhetsstrøm direkte fra kilden http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/list http://www.mynewsdesk.com/images/redesign/graphics/logos/logo-small.png 128 23 no 15 Tue, 19 Mar 2013 08:41:48 +0100 AbbVie AS, med hjemmeadresse på IT Fornebu i Bærum, er for femte året på rad kåret til et av Norges beste steder å jobbe i klassen for de mellomstore selskapene (mellom 50 og 250 ansatte). http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbvie-en-av-norges-beste-arbeidsplasser-847826?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbvie-en-av-norges-beste-arbeidsplasser-847826?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS Wed, 06 Feb 2013 11:17:00 +0100 Den europeiske kommisjonen har godkjent HUMIRA® (adalimumab) for behandling av barn mellom 6 og 17 år med alvorlig, aktiv Crohns sykdom (CD) som ikke har respondert på, eller som ikke tolererer / har kontraindikasjoner mot konvensjonell behandling. HUMIRA blir med dette den første biologiske behandlingsformen som godkjennes for denne pasientgruppen på fem år. http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbotts-humira-r-adalimumab-godkjent-for-alvorlig-aktiv-crohns-sykdom-hos-barn-834626?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbotts-humira-r-adalimumab-godkjent-for-alvorlig-aktiv-crohns-sykdom-hos-barn-834626?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS Thu, 03 Jan 2013 08:30:00 +0100 AbbVies utskillelse fra Abbott, markerer en ny satsing på utvikling av avanserte behandlinger for uløste helseproblemer. http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbvie-etablert-i-norge-verdens-nyeste-biofarmasoeytiske-selskap-825371?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbvie-etablert-i-norge-verdens-nyeste-biofarmasoeytiske-selskap-825371?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS Tue, 21 Aug 2012 13:54:00 +0200 HUMIRA blir det første og eneste godkjente legemidlet til behandling av alvorlig non-radiografisk aksial spondylartritt (nr-axSpA) hos voksne. http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbotts-humira-r-adalimumab-godkjent-i-europa-for-behandling-av-non-radiografisk-aksial-spondylartritt-nr-axspa-786232?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbotts-humira-r-adalimumab-godkjent-i-europa-for-behandling-av-non-radiografisk-aksial-spondylartritt-nr-axspa-786232?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS Tue, 21 Aug 2012 13:49:00 +0200 HUMIRA Becomes First and Only Approved Medication for the Treatment of Severe nr-axSpA in Adults. http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-s-humira-r-adalimumab-approved-in-europe-for-treatment-of-non-radiographic-axial-spondyloarthritis-nr-axspa-786229?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-s-humira-r-adalimumab-approved-in-europe-for-treatment-of-non-radiographic-axial-spondyloarthritis-nr-axspa-786229?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS Wed, 20 Jun 2012 12:28:00 +0200 Great Place to Work Institute® Names Abbott One of the Best Workplaces in Europe for the Third Consecutive Year http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-again-named-one-of-the-best-workplaces-in-europe-774011?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-again-named-one-of-the-best-workplaces-in-europe-774011?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS Wed, 11 Apr 2012 18:38:00 +0200 HUMIRA® blir den første og eneste selvinjiserte biologiske behandlingsformen for moderat til alvorlig aktiv UC hos voksne. http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbotts-humira-r-adalimumab-godkjent-i-europa-for-behandling-av-ulceroes-kolitt-uc-749781?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbotts-humira-r-adalimumab-godkjent-i-europa-for-behandling-av-ulceroes-kolitt-uc-749781?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS Wed, 11 Apr 2012 18:36:00 +0200 HUMIRA® Becomes First and Only Self-injectable Biologic Therapy for the Treatment of Moderately to Severely Active UC in Adults. http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-s-humira-r-adalimumab-approved-in-europe-for-treatment-of-ulcerative-colitis-uc-749784?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-s-humira-r-adalimumab-approved-in-europe-for-treatment-of-ulcerative-colitis-uc-749784?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS Thu, 22 Mar 2012 09:04:00 +0100 Company Remains on Track for Separation into Two Publicly Traded Global Health Care Companies by End of 2012 ABBOTT PARK, Ill., March 21, 2012 – Abbott today announced that AbbVie [pronounced Abb-vee] will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012. http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-selects-abbvie-as-new-name-for-future-research-based-pharmaceutical-company-744261?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-selects-abbvie-as-new-name-for-future-research-based-pharmaceutical-company-744261?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS Thu, 26 Jan 2012 08:53:02 +0100 Abbott today announced financial results for the fourth quarter ended Dec. 31, 2011. http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-reports-double-digit-ongoing-earnings-per-share-growth-in-fourth-quarter-and-full-year-2011-726885?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-reports-double-digit-ongoing-earnings-per-share-growth-in-fourth-quarter-and-full-year-2011-726885?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS Mon, 09 Aug 2010 14:18:52 +0200 We understand well at Abbott that our citizenship work is never done," said Miles D. White, chairman and chief executive officer, Abbott. "We will keep working to embed citizenship in every aspect of our operations and to build a continually more sustainable business. http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-2009-global-citizenship-report-449648?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-2009-global-citizenship-report-449648?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS Mon, 09 Aug 2010 14:12:00 +0200 Great Place to Work Institute® Europe Names Abbott One of the Best Workplaces in Europe; In 2010, Abbott Receives Workplace Honors in 16 Countries - also in Norway. http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-honored-as-a-great-place-to-work-across-europe-449644?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/no/pressroom/abbvie-as/pressrelease/view/abbott-honored-as-a-great-place-to-work-across-europe-449644?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AbbVie AS